
    
      A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP)
      Versus Gemcitabine Plus Carboplatin (GC) as First-Line Treatment in Patients With Advanced
      Triple-Negative Breast Cancer.
    
  